Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen

Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 2040 patients and caused 712 deaths since its first appearance in 2012, yet neither pathogen-specific therapeutics nor approved vaccines are available. To address this need, we are developing a subunit recombinant protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyon, Mun Peak, Du, Lanying, Tseng, Chien-Te Kent, Seid, Christopher A., Pollet, Jeroen, Naceanceno, Kevin S., Agrawal, Anurodh, Algaissi, Abdullah, Peng, Bi-Hung, Tai, Wanbo, Jiang, Shibo, Bottazzi, Maria Elena, Strych, Ulrich, Hotez, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860679/
https://www.ncbi.nlm.nih.gov/pubmed/29496347
http://dx.doi.org/10.1016/j.vaccine.2018.02.065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860679/
https://www.ncbi.nlm.nih.gov/pubmed/29496347
http://dx.doi.org/10.1016/j.vaccine.2018.02.065

Ejemplares similares